Skip to content

The Oncology Institute, Inc. TOI Operating Lease Right-of-Use Assets in Other Assets

Operating Lease Right-of-Use Assets in Other Assets at other companies

McKesson logo
McKessonMCK
Evolent Health, Inc. logo
Evolent Health, Inc.EVH
Immunome logo
ImmunomeIMNM
Option Care Health, Inc. logo
Option Care Health, Inc.OPCH
Summit Therapeutics logo
Summit TherapeuticsSMMT
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG

Other financials

Income statement

See full
Revenue$147.4M+41.2%
Operating income-$6.5M+34.3%
Net income-$2.5M+87.3%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$30.3M-23.8%
Total debt$104.9M+2.5%
Total equity-$16.3M-421%
Total assets$168.2M+2.6%

Cash flow

See full
Operating cash flow-$2.2M+55.6%
CapEx$1.0M+218%
Free cash flow-$3.3M+38.7%

Valuation

See full
Market cap$511.91M+133%
Enterprise value$586.58M+108%
P/S0.9×+0.4×

Profitability

See full
Operating margin-6%-2.1pp
Net margin-8%-2.7pp
FCF margin-5.1%

Returns & leverage

See full
Return on equity-277.6%-700pp
Debt / equity20.2×+17.3×
Current ratio1.5×-0.3×

Where this comes from

Reported directly by The Oncology Institute, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Oncology Institute, Inc.'s operating lease right-of-use assets in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is The Oncology Institute, Inc.'s operating lease right-of-use assets in other assets?
The Oncology Institute, Inc. (TOI) reported operating lease right-of-use assets in other assets of $22.52M in Q1 2026.
How has The Oncology Institute, Inc.'s operating lease right-of-use assets in other assets changed year-over-year?
The Oncology Institute, Inc.'s operating lease right-of-use assets in other assets decreased by 7.0% year-over-year, from $24.21M to $22.52M.